₹49.93 Crores | Listing at BSE, NSE | Wed, Jul 23, 2025 - Thu, Aug 21, 2025
Kilitch Drugs (india) Ltd. Rights Issue comprises 0.1398 Cr equity shares aggregating to ₹49.93 Cr, offered at an issue price of ₹357 per share with a face value of ₹10 per share.
The record date for determining eligible shareholder is Jul 15, 2025, with the Rights Issue being offered in the entitlement ratio of 2 : 23.
The term of payment is defined as following : The full amount of the Issue Price Rs 357/- will be payable on application.
The Rights Entitlements are expected to be credited to eligible demat accounts on Aug 22, 2025.
The Rights Issue opens on Jul 23, 2025, and closes on Aug 21, 2025, with renunciation of Rights Entitlements permitted up to Aug 18, 2025.
The deemed date of allotment is Aug 22, 2025, following which the equity shares are expected to be credited to demat accounts on Aug 26, 2025 and listed at the NSE and the BSE on Aug 28, 2025.
MUFG Intime India Pvt.Ltd. is the Registrar to the Issue.
Investors are advised to refer to the Kilitch Drugs (india) Ltd. Letter of Offer for detailed information, including risk factors, issue terms, and procedural details.
Record Date
Tue, Jul 15, 2025
Entitlement Ratio
2 : 23
Open Date
Wed, Jul 23, 2025
Close Date
Thu, Aug 21, 2025
The full amount of the Issue Price Rs 357/- will be payable on application.
Kilitch Drugs (india) Ltd.'s revenue increased by 28% and profit after tax (PAT) rose by 84% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 |
| Revenue | 198.32 | 154.37 |
| Profit After Tax | 24.94 | 13.58 |
| Net Worth | 202.33 | 176.29 |
| Reserves and Surplus | 186.25 | 160.21 |
| Amount in ₹ Crore | ||
Incorporated in 1992, Kilitch Drugs (India) Ltd, specializes in manufacturing and exporting pharmaceutical formulations. It serves over 38 countries, focusing on injectables, oral solids, nutraceuticals, and ophthalmic products across emerging markets.
The company operates facilities in India and Ethiopia. Its upcoming Khopoli plant will manufacture diabetes, weight-loss drugs, and biosimilars, with plans for US-FDA and EU approvals in future phases.
The company engages in the development, manufacturing, and marketing of a wide range of products: oral solids, injectables, ophthalmic, nasal formulations, nutritional supplements, medical devices, and cosmetics.
The Company intends to utilize the Net Proceeds from the Issue towards funding of the following objects:
[Dilip Davda] KDIL is engaged in the manufacturing/marketing/ and supply of wide range of pharmaceutical products. The company posted growth in its top and bottom lines for the last two fiscals. Based on its recent financial data, the issue appears fully priced. Despite profits, it has skipped dividends for last two fiscals, that remains major concern. The issue is at a discount of around 19.77%. Well-informed investors may park funds for medium to long term. Read detail review...
Kilitch Drugs (india) Rights Issue 2025 got oversubscribed by 1.19 times by the end of the bidding period with total bid quantity received by BSE and NSE of 16,71,097 shares. Check Day by Day Subscription Details (Live Status)
| Date | BSE Bid Quantity | NSE Bid Quantity | Total Bid Quantity | Subscription Times |
|---|---|---|---|---|
Aug 21 2025 17:00:00 | 12,94,081 | 3,77,016 | 16,71,097 | 1.19x |
Kilitch Drugs (india) Ltd.
C-301/2 MIDC,
TTC Industrial Area,
Pawane Village, Thane,
Mumbai, 400705
The Kilitch Drugs (india) Rights Issue 2025 opens on Wed, Jul 23, 2025, and closes on Thu, Aug 21, 2025.
Kilitch Drugs (india) Rights Issue 2025 Schedule
| Last Date for credit of Rights Entitlements | Wed, Jul 16, 2025 |
| Last Date for renunciation of Rights Entitlements | Mon, Aug 18, 2025 |
| Issue Opening Date | Wed, Jul 23, 2025 |
| Issue Closing Date | Thu, Aug 21, 2025 |
| Date of Allotment (on or about) | Fri, Aug 22, 2025 |
| Date of Credit (on or about) | Tue, Aug 26, 2025 |
| Date of Listing (on or about) | Thu, Aug 28, 2025 |
You can apply for Kilitch Drugs (india) Rights Issue 2025 in two ways:
Steps to apply for Kilitch Drugs (india) Rights Issue 2025 using Net Banking (ASBA)
Steps to apply for Kilitch Drugs (india) Rights Issue 2025 using Registrar's website (R-WAP)
